NeuroMetrix (NURO) Tops Q3 EPS by 6c

NeuroMetrix (NASDAQ: NURO) reported Q3 EPS of ($0.76), $0.06 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $3.39 million versus the consensus estimate of $3.01 million.

Recent Highlights:

• Quell shipments totaled 12,086 devices and 14,391 electrode reorder packages with a total invoiced value of $2.90 million in Q3 2016. This was an increase from 11,201 devices and 10,237 electrode reorder packages with a total invoiced value of $2.53 million in Q2 2016.
• The Company announced that a clinical study by Brigham and Women’s Hospital in Boston will assess the utility of Quell technology in patients with chronic low back pain.
• DPNCheck shipments in Q3 2016 reached a 4 year high of 57,400 biosensors, up 45% from 39,500 biosensors in Q3 2015.
• Final DPNCheck regulatory approval was obtained from the China Food and Drug Administration.
• A patent was issued in China for the core DPNCheck technology.

For earnings history and earnings-related data on NeuroMetrix (NURO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49